Arrowhead Pharmaceuticals Inc. Common Stock (ARWR)
Stock · NASDAQ · Health Care
$55.88as of 10/16/2026
Price chart
Active signals
ARWR Signal Track Record
How signals performed across all stocks →What ARWR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +4.5% | 57% | September 1, 2026 |
| Bollinger Band Breakout | 25 | -2.9% | 48% | April 9, 2026 |
| Bollinger Band Breakdown | 18 | -1.1% | 50% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -5.5% | 40% | July 15, 2025 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNA…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 711
- Website
- arrowheadpharma.com/
Fundamentals
- 1-day range
- $55.83$58.45
- Market cap
- $12.12B
- P/E (trailing)
- —
- P/E (forward)
- -11.23
- EPS (trailing)
- $-2.24
- Dividend yield
- —
- Beta
- 1.34
- Avg. volume
- 1.89M
How Arrowhead Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 25, 2025 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Arrowhead Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$449.74▼ 2.19%Market cap $11.79BP/E —$393.61$615
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $449.74 | ▼ 2.19% | $393.61$615 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Targetbenzinga · 10/15/2026
- 3 Biotech Stocks To Watch In October 2026Yahoo · 10/10/2026
- Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe HypertriglyceridemiaYahoo · 10/7/2026
- Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million VoucherSeekingAlpha · 10/2/2026
- Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesYahoo · 9/29/2026
- RNAi drug specialist ADARx raises $446M IPOYahoo · 9/25/2026
- ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts NearYahoo · 9/24/2026
- Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price TargetBenzinga · 9/24/2026
- Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market TodayBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Michael S. Perry · August 18, 2026 · Sale11.6K @ $87.3
- Adeoye Y. Olukotun · August 18, 2026 · Sale2.0K @ $86.96
- Hongbo Lu · May 12, 2026 · Sale3.0K @ $76.88
- James C. Hamilton · April 23, 2026 · Sale10.0K @ $75
- Daniel Joseph Apel · April 22, 2026 · Sale8.7K @ $71.92
- Daniel Joseph Apel · April 22, 2026 · Sale1.2K @ $70.45
- Daniel Joseph Apel · April 22, 2026 · Sale3.2K @ $70.11
Institutional Ownership
March 31, 2026
- Total shares held
- 114.19M
- Total value held
- $7.03B
- Institutional holders
- 431
- Unknown18.16M
- Unknown10.70M
- Unknown7.27M
- Unknown6.50M
- Unknown6.03M
- Unknown4.28M
- Unknown3.34M
- Unknown3.28M
- Unknown2.27M
- Unknown1.99M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.